In addition, gene therapy approaches such as antisense oligonucleotide (ASO) technology have shown promising results in reducing cyst formation in CEP290-related renal disease models (35) and may represent a potential precision treatment strategy for TMEM216-related kidney disorders in the future. This evidence concerns the gene TMEM216 and kidney disorder.